Skip to content

Inspection of the usefulness of the Cell-free and concentrated Ascites Reinfusion Therapy (CART) by the cryopreservation ascites.

Inspection of the usefulness of the Cell-free and concentrated Ascites Reinfusion Therapy (CART) by the cryopreservation ascites. - Non randomized controlled trial by the cryopreservation ascites.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000019847
Enrollment
50
Registered
2015-11-18
Start date
2014-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cander, Tubal carcinoma, Cervical cancer, Endometrial cancer, Primary peritoneal cancer, Liver cancer, Liver cirrhosis, Lung cancer, Gastric cancer, Colon cancer, Rectal cancer

Interventions

Allocate the case that the ascites are submitted to our division before 14:00 on the non-preservation ascites group. The ascites in that group are not performed safekeeping and CART is carried out

Sponsors

Department of Transfusion Medicine and Cell Processing, Tokyo Women's Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age over20-years old. 2. Patients who voluntarily provided written consent to participate in this trial after having been thoroughly briefed and informed of its nature were eligible for enrollment.

Exclusion criteria

Exclusion criteria: 1. The patient who is higher than Serum bilirubin level 5mg/dL. 2. The patient that an infectious disease is strongly doubted by fever, abdominal symptom or high CRP level. 3. The patient with less than 1,000mL of gathered ascites (or pleural fluids). 4. The patient that hemolysis of the ascites is observed. 5. Other patients judged to be ineligible by the attending investigators.

Design outcomes

Primary

MeasureTime frame
Equivalency of the clinical manifestations improvement effect in the cryopreservation ascites group and the control group Inspection of the side effect reduction effect in the preservation cryopreservation ascites group.

Secondary

MeasureTime frame
In the preservation cryopreservation ascites group, 1. Change of various ascites components (pH, general biochemistry, cytokine) before and after the preservation. In the both groups, 1.Correlation of quantity of cytokine in the ascites and fever caused in the reinfusion. 2. Confirmation of safety by the examination for endotoxin. 3. Change of the blood test level before and after the treatment.

Countries

Japan

Contacts

Public ContactTaiju Utugisawa

Tokyo Women's Medical University Department of Transfusion Medicine and Cell Processing

utsugisawa.taiju@twmu.ac.jp+81-3-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026